Table 1. Summary of canine F.IX antigen... | American Society of Hematology

Table 1.

Summary of canine F.IX antigen and clotting activity in hemophilia B dogs following delivery of AAV2-CMV-cF.IX by isolated limb perfusion or by intravenous injection

	Age at time of injection, mo	Gender	Weight, kg	Route	Vector genome/kg	Circulating cF.IX, ng/mL	aPTT,^*sec	F.IX^*activity, %	Inhibitor to cF.IX	Follow-up, mo
Experimental
D99	15	Female	16.7	ILP	3.7 × 10¹²	730 ± 60	20 ± 2	15 ± 2	No	39
F57	4.5	Male	12	ILP	1.7 × 10¹²	260 ± 52	28 ± 4	5.5 ± 1.3	No	27
H08	6	Male	17.2	ILP	3.0 × 10¹²	210 ± 16	32 ± 3	4.2 ± 1.5	No	8
Control
E60†	6	Female	22.5	ILP	3.9 × 10¹²	0	More than 50	Less than 1	Yes	≈ 10
E59	3	Female	14.5	IV	2.9 × 10¹²	31-78	41 ± 3	1 ± 0.4	No	37

	Age at time of injection, mo	Gender	Weight, kg	Route	Vector genome/kg	Circulating cF.IX, ng/mL	aPTT,^*sec	F.IX^*activity, %	Inhibitor to cF.IX	Follow-up, mo
Experimental
D99	15	Female	16.7	ILP	3.7 × 10¹²	730 ± 60	20 ± 2	15 ± 2	No	39
F57	4.5	Male	12	ILP	1.7 × 10¹²	260 ± 52	28 ± 4	5.5 ± 1.3	No	27
H08	6	Male	17.2	ILP	3.0 × 10¹²	210 ± 16	32 ± 3	4.2 ± 1.5	No	8
Control
E60†	6	Female	22.5	ILP	3.9 × 10¹²	0	More than 50	Less than 1	Yes	≈ 10
E59	3	Female	14.5	IV	2.9 × 10¹²	31-78	41 ± 3	1 ± 0.4	No	37

Activated partial thromboplastin time (aPTT) for normal dogs: 16.5 ± 3.0 seconds; for untreated hemophilia B dogs: longer than 50 seconds.

ILP indicates isolated limb perfusion; IV, intravenous.

Values represent data from several time points (D99 and F57 from 2 to 26 months, H08 from 2 to 8 months)

†

Animal did not receive cyclophosphamide

View Large

This Feature Is Available To Subscribers Only